Genome Publications
https://doi.org/10.61096/978-81-981372-2-7_15

Chapter 15

Musculoskeletal and Bone Disorders

Srinivas Venkatraman
JKKMMRF'S – Annai JKK Sampoorani Ammal College of Pharmacy,
Komarapalayam, Namakkal, Tamilnadu. 638 183, India.
Kannan Raman
St. Johns College of Pharmaceutical Sciences & Research,
Kattappana, Idukki, Kerala – 685515, India.
Prasanth R
JKKMMRF'S – Annai JKK Sampoorani Ammal College of Pharmacy,
Komarapalayam, Namakkal, Tamilnadu. 638 183, India.

Abstract: Musculoskeletal and bone disorders constitute a significant global health burden, particularly in aging populations where degenerative, inflammatory, and metabolic changes converge to compromise mobility, independence, and quality of life. The intricate interplay between systemic inflammation, age-related remodeling imbalances, endocrine dysregulation, and mechanical stress underpins the pathogenesis of conditions such as osteoporosis, osteoarthritis, sarcopenia, and inflammatory arthritis. This chapter explores the pharmacological, biological, and supportive interventions aimed at preserving skeletal integrity and musculoskeletal function. It begins with an overview of bone remodeling pharmacology, focusing on the modulation of osteoclasts and osteoblasts as therapeutic targets. The roles of anti-resorptive therapies such as bisphosphonates and denosumab are examined alongside emerging concerns of long-term adverse effects, including osteonecrosis of the jaw and atypical fractures. In parallel, anabolic bone agents including parathyroid hormone analogs and the novel sclerostin inhibitor romosozumab are discussed for their ability to stimulate bone formation. Considerable attention is given to pharmacological disease-modifying strategies for osteoarthritis, current limitations in achieving true structural modification, and reliance on symptomatic agents. Furthermore, the chapter integrates discussions on NSAID-related safety considerations, novel therapeutics for sarcopenia such as myostatin inhibitors, and the growing role of biologics in inflammatory arthritides. Localized therapies, nutritional strategies, and lifestyle interventions are also evaluated, highlighting multidisciplinary approaches required for effective management. Through a synthesis of recent research, clinical practice, and future perspectives, this chapter emphasizes the evolving therapeutic landscape of musculoskeletal and bone disorders.

Keywords: Osteoporosis, Osteoarthritis, Biologics, Sarcopenia, Bone Remodeling.

Citation: Srinivas Venkatraman, Kannan Raman, Prasanth R. Musculoskeletal and Bone Disorders. ***Precision Therapeutics Across Organ Systems. Genome Publications.*** **2025; Pp154-165.** https://doi.org/10.61096/978-81-981372-2-7_15

15.0 INTRODUCTION

Musculoskeletal (MSK) and bone disorders represent some of the most common chronic conditions worldwide, affecting hundreds of millions of individuals and posing a significant socioeconomic burden. These disorders encompass a spectrum ranging from metabolic bone diseases such as osteoporosis to degenerative joint diseases such as osteoarthritis, inflammatory arthritides like rheumatoid arthritis, and age-related conditions including sarcopenia. Their prevalence rises sharply with age, and with the global population aging, the incidence and associated disability are projected to increase substantially. The economic costs extend beyond healthcare utilization to include productivity losses, disability, and the need for long-term care [1].

The biology of MSK disorders is tightly linked to the balance between bone formation and resorption, muscle protein synthesis and degradation, and systemic factors such as hormones, cytokines, and nutrition. Aging introduces a decline in osteoblast function and an increase in osteoclast activity, predisposing individuals to bone fragility. Simultaneously, chronic low-grade inflammation or "inflammaging" exacerbates musculoskeletal deterioration by accelerating joint degeneration and impairing muscle regeneration [2]. These changes are compounded by lifestyle factors, reduced physical activity, and comorbidities such as diabetes, chronic kidney disease, and cardiovascular disorders, which further alter skeletal homeostasis.

Pharmacological interventions in musculoskeletal medicine have advanced significantly, moving from symptomatic pain relief to targeted biological therapies capable of modifying disease processes. Anti-resorptive agents have revolutionized osteoporosis management, while the advent of monoclonal antibodies has transformed the treatment landscape of inflammatory arthritis. Nevertheless, several gaps remain. For instance, truly disease-modifying osteoarthritis drugs (DMOADs) are still elusive, and sarcopenia remains a therapeutic frontier with few approved pharmacological options. This chapter provides a comprehensive evaluation of current and emerging therapeutic approaches, addressing their mechanisms, clinical evidence, limitations, and future prospects.



Figure 15.1: Pharmacological targets in bone remodeling and musculoskeletal disorders.

The diagram illustrates the bone remodeling cycle with osteoclast inhibition by anti-resorptive agents (bisphosphonates, denosumab), osteoblast stimulation by anabolic drugs (PTH analogs, romosozumab), and emerging disease-modifying approaches in osteoarthritis (sprifermin, ADAMTS-5 inhibitors, anti–nerve growth factor antibodies). NSAIDs act through COX-1/COX-2 inhibition to reduce prostaglandin synthesis, providing pain relief but with gastrointestinal, renal, and cardiovascular safety considerations.

15.0.1 Aging, Inflammation, and Bone Health

The musculoskeletal system undergoes profound age-related changes that predispose individuals to fractures, frailty, and reduced quality of life. Bone mass peaks in early adulthood and declines steadily after the age of 40, with accelerated losses in postmenopausal women due to estrogen deficiency. Osteoblast activity diminishes with age, whereas osteoclast-mediated bone resorption remains relatively preserved or heightened, leading to net bone loss [3]. This remodeling imbalance is influenced by cellular senescence, oxidative stress, and impaired signaling in key pathways such as Wnt/β-catenin, RANK/RANKL/OPG, and sclerostin-mediated inhibition [4].

Aging is also associated with chronic systemic inflammation, often termed “inflammaging.” Elevated pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein contribute to bone resorption and cartilage breakdown. These cytokines also impair muscle regeneration and accelerate sarcopenia, creating a vicious cycle of musculoskeletal decline [5]. In addition, immunosenescence alters the regulatory balance between effector and regulatory T cells, further promoting tissue damage in bone and joints. Experimental evidence suggests that anti-inflammatory interventions can mitigate these effects, highlighting the immunological basis of many MSK disorders.

Clinically, these age- and inflammation-driven changes manifest as osteoporosis-related fractures, osteoarthritis-associated pain and disability, and reduced mobility from sarcopenia. Management strategies must therefore target not only bone and joint pathology but also systemic contributors such as metabolic health, nutrition, and lifestyle factors. This integrated approach is critical to delaying disability and maintaining independence in the aging population.

15.1 Bone Remodeling Pharmacology

Bone is a dynamic tissue undergoing continuous remodeling through the coupled activities of osteoclasts and osteoblasts. This remodeling cycle is crucial for maintaining skeletal strength, repairing microdamage, and regulating mineral homeostasis. Pharmacological manipulation of these processes forms the cornerstone of therapy for bone-related disorders, particularly osteoporosis. Therapeutic strategies broadly target either osteoclasts to inhibit bone resorption or osteoblasts to promote bone formation.

The central regulatory pathway involves the receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, and the decoy receptor osteoprotegerin (OPG). Binding of RANKL to RANK stimulates osteoclast differentiation and activation, while OPG inhibits this process by sequestering RANKL. Drugs such as denosumab exploit this pathway by neutralizing RANKL and thereby reducing osteoclast activity [6]. Similarly, bisphosphonates act by binding to hydroxyapatite surfaces and inhibiting osteoclast-mediated bone resorption through disruption of the mevalonate pathway.

Osteoblast regulation is mediated by anabolic signaling cascades including Wnt/β-catenin, bone morphogenetic proteins (BMPs), and parathyroid hormone (PTH). Agents such as teriparatide and abaloparatide mimic PTH activity to stimulate osteoblast function. More recently, romosozumab,

a monoclonal antibody against sclerostin, has demonstrated dual activity by promoting bone formation and reducing bone resorption [7]. These mechanistic insights have expanded therapeutic options beyond conventional anti-resorptives, offering new strategies for patients at high fracture risk.

Despite these advances, challenges persist. Anti-resorptive therapies carry risks of long-term complications such as atypical femoral fractures and osteonecrosis of the jaw, while anabolic agents are limited by high cost and treatment duration restrictions. Future approaches aim to refine patient stratification and develop combination regimens that maximize skeletal benefits while minimizing adverse outcomes.

15.1.1 Osteoclast and Osteoblast Modulation

The pharmacological modulation of osteoclasts and osteoblasts represents a therapeutic balancing act. Osteoclast inhibitors, including bisphosphonates and denosumab, have shown substantial efficacy in reducing vertebral and non-vertebral fracture risk. Bisphosphonates such as alendronate and zoledronic acid act by disrupting osteoclast cytoskeletal function and inducing apoptosis. Denosumab, by contrast, provides a reversible and more direct inhibition of osteoclastogenesis through RANKL blockade [8]. These agents are widely used as first-line therapies but require careful monitoring due to potential adverse effects.

On the anabolic side, PTH analogs such as teriparatide stimulate osteoblast differentiation and prolong their survival. These drugs are particularly valuable for patients with severe osteoporosis and recurrent fractures. Romosozumab extends this paradigm by simultaneously activating bone formation pathways and inhibiting resorption, offering superior gains in bone mineral density compared to either approach alone [9]. Clinical trials such as FRAME and ARCH have demonstrated significant reductions in fracture incidence with romosozumab, albeit with some concerns regarding cardiovascular safety.

Importantly, the interplay between osteoclast and osteoblast modulation has inspired interest in sequential and combination therapies. For example, initiating therapy with anabolic agents followed by anti-resorptives appears to consolidate bone mass gains more effectively than monotherapy. This strategy highlights the need for dynamic treatment planning that reflects the biology of bone remodeling cycles. Ongoing research is also exploring novel modulators such as cathepsin K inhibitors, Wnt activators, and integrin-targeting drugs, which may further diversify therapeutic possibilities.

15.2 Anti-Resorptive Agents

Anti-resorptive agents constitute the most widely prescribed class of drugs for osteoporosis management. Their primary mechanism involves suppression of osteoclast-mediated bone turnover, thereby stabilizing or increasing bone mineral density (BMD) and reducing fracture risk. The mainstays of this category are bisphosphonates and denosumab, each with distinct pharmacological characteristics and clinical considerations.

Bisphosphonates, available in oral (alendronate, risedronate, ibandronate) and intravenous (zoledronic acid) formulations, are synthetic analogs of pyrophosphate that bind to hydroxyapatite in bone. Upon uptake by osteoclasts during bone resorption, nitrogen-containing bisphosphonates inhibit farnesyl pyrophosphate synthase in the mevalonate pathway, leading to impaired prenylation of small GTPases essential for osteoclast function [10]. This results in osteoclast apoptosis and decreased bone turnover. Long-term studies confirm their efficacy in fracture prevention, but

therapy beyond 5 years may necessitate “drug holidays” to mitigate risks of atypical femur fractures and osteonecrosis of the jaw.

Denosumab, a fully human monoclonal antibody targeting RANKL, provides potent and reversible inhibition of osteoclast differentiation and survival. Administered subcutaneously every six months, it has demonstrated superior increases in BMD compared with bisphosphonates and effective fracture risk reduction across multiple skeletal sites [11]. However, abrupt discontinuation of denosumab has been associated with rebound bone loss and multiple vertebral fractures, necessitating transition to alternative therapy upon withdrawal.

The comparative advantages of bisphosphonates include their low cost and extensive safety data, whereas denosumab offers convenience and stronger efficacy in high-risk patients. Limitations of both classes underscore the need for individualized therapy selection and long-term monitoring. Emerging anti-resorptive strategies, such as cathepsin K inhibitors (odanacatib) and integrin antagonists, are under investigation but face challenges related to off-target effects and safety concerns. Collectively, anti-resorptives remain indispensable in osteoporosis management, though their future may lie in combination with anabolic or immunomodulatory agents for optimized outcomes.

15.3 Anabolic Bone Agents

Anabolic bone agents represent a transformative advance in osteoporosis therapy by directly stimulating new bone formation rather than simply preventing resorption. Their development arose from recognition that patients with severe osteoporosis or recurrent fragility fractures require bone-building therapies to restore structural integrity. The main approved anabolic agents include parathyroid hormone (PTH) analogs such as teriparatide and abaloparatide, as well as romosozumab, a monoclonal antibody against sclerostin [12].

Teriparatide, a recombinant fragment of PTH (1–34), exerts anabolic effects when administered intermittently, stimulating osteoblast differentiation, increasing bone turnover, and enhancing bone mineral density (BMD) particularly at trabecular sites. Clinical trials such as the Fracture Prevention Trial demonstrated significant reductions in vertebral and nonvertebral fractures with teriparatide therapy [13]. Abaloparatide, a synthetic analog of PTH-related peptide, offers similar efficacy with potentially lower risks of hypercalcemia. Both agents are limited to a maximum of two years of use due to concerns over osteosarcoma observed in animal studies, though this has not been clearly demonstrated in humans [14].

Romosozumab represents a new class of dual-action agents by simultaneously stimulating bone formation and inhibiting resorption through inhibition of sclerostin, an osteocyte-secreted protein that negatively regulates Wnt/β-catenin signaling. The FRAME and ARCH trials demonstrated that romosozumab significantly increased BMD and reduced fracture risk more effectively than alendronate or placebo [15]. However, concerns about a potential increase in cardiovascular events have tempered enthusiasm and restricted its use in patients with high cardiovascular risk [16].

The clinical utility of anabolic agents is optimized when followed by anti-resorptive therapy, which helps maintain the bone mass accrued during anabolic treatment. Sequential therapy has emerged as a best-practice strategy for high-risk osteoporosis patients. Future developments aim to extend anabolic effects through novel agents such as activators of BMP signaling, inhibitors of sclerostin variants, or combined anabolic–anti-resorptive approaches.

15.3.1 PTH Analogs and Romosozumab

The efficacy of PTH analogs is rooted in their ability to preferentially stimulate bone formation over resorption when administered intermittently. Unlike continuous exposure, which leads to bone resorption, once-daily subcutaneous injections of teriparatide or abaloparatide activate osteoblasts and enhance trabecular architecture. Patients with severe osteoporosis, glucocorticoid-induced bone loss, or multiple vertebral fractures benefit most from these agents [17].

Romosozumab extends this paradigm by directly modulating osteocyte signaling. Sclerostin, encoded by the SOST gene, acts as a negative regulator of osteoblast activity. Inhibition of sclerostin by romosozumab increases osteoblast-driven bone deposition and concurrently reduces osteoclast activity, producing rapid gains in BMD. In the ARCH study, romosozumab followed by alendronate reduced vertebral fractures by 48% compared with alendronate alone [18]. However, cardiovascular safety signals observed in some trials prompted regulatory agencies to limit use in patients with recent myocardial infarction or stroke [19].

Despite these concerns, the therapeutic potential of anabolic bone agents remains substantial. They provide a unique opportunity to rebuild skeletal structure in patients at imminent fracture risk. Clinical guidelines now recommend PTH analogs or romosozumab as initial therapy in patients with multiple fragility fractures or very low BMD, followed by long-term anti-resorptive therapy to sustain benefits. The evolving role of these drugs exemplifies the precision tailoring of therapy based on patient risk profile and response.

15.4 Osteoarthritis Therapies

Osteoarthritis (OA) is the most prevalent joint disorder worldwide and a leading cause of pain and disability. Its pathogenesis involves a complex interplay of mechanical stress, cartilage degradation, synovial inflammation, and subchondral bone remodeling. Pharmacological therapies have traditionally focused on symptom management, with NSAIDs and intra-articular injections providing relief but no structural modification. This has fueled intense research into disease-modifying osteoarthritis drugs (DMOADs) aimed at halting or reversing structural progression [20].

Current DMOAD candidates target pathways implicated in cartilage degradation, including inhibitors of matrix metalloproteinases, ADAMTS-5 (a key aggrecanase), and cathepsin K. Small-molecule agents, monoclonal antibodies, and gene therapies have been investigated, though many have failed due to insufficient efficacy or safety concerns. For instance, sprifermin, a recombinant fibroblast growth factor 18, has shown promise in stimulating cartilage thickness in knee OA, though its impact on symptoms remains modest [21]. Similarly, monoclonal antibodies against nerve growth factor (e.g., tanezumab) have demonstrated significant analgesic effects, but their use has been limited by concerns about rapidly progressive OA and joint damage [22].

The dichotomy between structural and symptomatic benefits underscores the challenges of developing effective OA therapies. Current practice remains centered on analgesics, intra-articular corticosteroids, and viscosupplements such as hyaluronic acid, while lifestyle modifications including exercise and weight management remain essential. The pursuit of DMOADs continues, with ongoing trials exploring gene therapy, stem-cell–based injections, and novel anti-inflammatory biologics. Until these become clinically viable, OA management will remain largely symptomatic.

15.4.1 DMOADs Development

The development of DMOADs reflects an unmet clinical need to alter the course of OA progression. Sprifermin has emerged as a leading candidate, demonstrating significant increases in cartilage thickness in MRI-based analyses of knee OA patients. However, translation of these structural benefits into tangible improvements in pain and function has proven elusive, raising questions about appropriate trial endpoints [23]. Similarly, anti–nerve growth factor monoclonal antibodies such as tanezumab and fasinumab have provided superior analgesia compared with NSAIDs but are associated with adverse outcomes such as rapidly progressive joint damage [24].

Another area of interest involves targeting subchondral bone remodeling, with cathepsin K inhibitors and bisphosphonates evaluated for their ability to modify bone-cartilage interactions. While animal studies are promising, clinical translation remains limited. Gene therapy strategies delivering anabolic factors such as TGF-β or anti-inflammatory cytokines directly into joints are also under exploration, alongside mesenchymal stem cell–based regenerative approaches. Despite these advances, no agent has yet achieved regulatory approval as a true DMOAD.

Ultimately, the challenge lies in defining clinically meaningful outcomes beyond pain relief and incorporating biomarkers or imaging-based endpoints to demonstrate structural modification. The future of OA pharmacotherapy depends on bridging this gap between biological efficacy and patient-centered outcomes.

15.5 NSAIDs for MSK Pain

Nonsteroidal anti-inflammatory drugs (NSAIDs) remain the cornerstone of pain management in musculoskeletal disorders. Their mechanism of action involves inhibition of cyclooxygenase (COX) enzymes, thereby reducing prostaglandin synthesis and alleviating inflammation, pain, and stiffness. While highly effective for short-term symptom relief, chronic use of NSAIDs presents well-documented risks including gastrointestinal bleeding, renal impairment, and cardiovascular events [25].Traditional nonselective NSAIDs such as ibuprofen, naproxen, and diclofenac inhibit both COX-1 and COX-2, with COX-1 inhibition contributing to gastrointestinal toxicity. Selective COX-2 inhibitors (coxibs) such as celecoxib were developed to mitigate GI risks, but concerns emerged after some agents (rofecoxib, valdecoxib) were withdrawn due to increased cardiovascular events. Celecoxib remains available with a more favorable safety profile, but its use requires individualized cardiovascular risk assessment [26].

NSAID-related nephrotoxicity, including acute kidney injury and chronic interstitial nephritis, further complicates long-term use. Guidelines recommend using the lowest effective dose for the shortest possible duration, with gastroprotective agents such as proton pump inhibitors often co-prescribed for high-risk patients. Alternatives such as acetaminophen offer weaker analgesic effects, while opioids carry risks of dependence. Consequently, NSAIDs remain indispensable but imperfect tools for MSK pain, necessitating careful risk–benefit evaluation.

15.5.1 Chronic Use Considerations

Chronic NSAID use requires vigilance due to cumulative adverse effects. Gastrointestinal complications, including peptic ulcers and bleeding, remain the most significant risks, particularly in older adults and those with prior ulcer disease. Co-prescription of proton pump inhibitors reduces but does not eliminate this risk [27]. Renal complications are increasingly recognized, with NSAIDs implicated in reduced renal perfusion, papillary necrosis, and progression of chronic kidney disease. Cardiovascular concerns include heightened risk of myocardial infarction, stroke, and hypertension,

particularly with COX-2 selective inhibitors [28].

Clinical decision-making for long-term NSAID therapy involves stratification of patient risk profiles. For instance, naproxen is often considered safer from a cardiovascular perspective, whereas celecoxib offers improved gastrointestinal tolerability. The importance of shared decision-making is paramount, ensuring patients understand risks and benefits. The search for safer anti-inflammatory agents, including selective prostaglandin receptor modulators and novel analgesics, reflects ongoing unmet needs in musculoskeletal pain management.

Table 15.1: Comparative Mechanisms and Clinical Uses of Anti-Resorptive vs. Anabolic Bone Agents

Drug Class	Key Agents	Primary Mechanism of Action	Clinical Indications	Major Limitations / Adverse Effects
Anti-Resorptive Agents	Alendronate, Zoledronate	Inhibit osteoclast activity (via mevalonate pathway)	Osteoporosis, glucocorticoid-induced bone loss	Osteonecrosis of jaw, atypical femur fractures
	Denosumab	RANKL inhibition → decreased osteoclast survival	High fracture risk osteoporosis	Rebound bone loss after discontinuation
Anabolic Agents	Teriparatide, Abaloparatide	Intermittent PTH receptor stimulation → osteoblast activation	Severe osteoporosis, multiple fractures	Duration limited to 2 years; cost
	Romosozumab	Sclerostin inhibition → ↑ bone formation & ↓ resorption	Very high fracture risk osteoporosis	Possible cardiovascular risks

Table 15.2: Emerging Therapeutic Strategies for Osteoarthritis and Sarcopenia

Condition	Emerging Therapy	Mechanism / Target Pathway	Stage of Development	Challenges / Limitations
Osteoarthritis	Sprifermin (FGF-18)	Stimulates cartilage thickness	Phase II/III	Modest symptom benefit
	Tanezumab (anti–NGF antibody)	Analgesia via NGF inhibition	Phase III	Risk of rapidly progressive OA
	Cathepsin K inhibitors	Reduce subchondral bone resorption	Early clinical	Safety, efficacy not yet proven
Sarcopenia	Myostatin inhibitors (Bimagrumab)	Blockade of activin receptor signaling	Phase II/III	Limited functional improvement
	SARMs (Enobosarm)	Selective androgen receptor activation	Phase II/III	Safety concerns, regulatory hurdles
	Nutritional + exercise interventions	Muscle protein synthesis and functional training	Clinical practice	Requires adherence, variable patient response



Figure 15.2: Interplay of Aging, Inflammation, and Bone-Muscle Health

15.6 Sarcopenia Management

Sarcopenia, the progressive loss of muscle mass and function with aging, represents a growing public health concern as it predisposes individuals to falls, frailty, and loss of independence. Its multifactorial etiology includes decreased anabolic signaling, chronic inflammation, mitochondrial dysfunction, and reduced physical activity. Pharmacological management remains limited, with no therapies currently approved specifically for sarcopenia, though several experimental approaches show promise [29].

Myostatin, a member of the transforming growth factor-β (TGF-β) superfamily, is a potent negative regulator of muscle growth. Myostatin inhibitors, including monoclonal antibodies (e.g., bimagrumab) and ligand traps, have demonstrated increases in muscle mass in clinical studies, though improvements in strength and function remain inconsistent [30]. Other anabolic strategies involve selective androgen receptor modulators (SARMs), which promote muscle growth while minimizing androgenic side effects, and growth hormone secretagogues. Nutritional interventions, particularly adequate protein intake and vitamin D supplementation, remain central to sarcopenia management. Exercise, particularly resistance training, remains the most effective intervention for improving muscle strength and physical performance.

Cachexia associated with chronic diseases such as cancer or heart failure presents additional challenges, where muscle wasting is exacerbated by systemic inflammation and catabolic signaling. Emerging therapies targeting inflammatory cytokines or metabolic pathways hold potential, but clinical translation is ongoing. Ultimately, sarcopenia management will likely require combination approaches integrating pharmacological, nutritional, and lifestyle strategies.

15.6.1 Myostatin Inhibitors and Muscle Growth Modulators

Myostatin inhibition has been the most extensively studied pharmacological approach to sarcopenia. Bimagrumab, an anti–activin receptor type II monoclonal antibody, demonstrated promising results in early trials with significant gains in lean muscle mass. However, subsequent phase III trials failed to show consistent functional benefits, highlighting the complexity of translating increased muscle mass into improved clinical outcomes [31]. Similar results have been observed with other myostatin antagonists, reflecting the need for multi-targeted strategies.

SARMs such as enobosarm (ostarine) have also been investigated, showing positive effects on muscle mass and function in older adults and cancer patients. However, safety concerns, including potential hepatic toxicity and off-target effects, have limited progress toward regulatory approval [32]. Combination therapies that integrate pharmacological agents with exercise interventions may offer the most effective approach, leveraging the physiological benefits of resistance training to complement pharmacological muscle anabolism.

Emerging interest has also focused on metabolic modulators, mitochondrial enhancers, and anti-inflammatory biologics as adjunctive therapies. As research advances, the integration of pharmacological muscle growth modulators with holistic strategies including nutrition, exercise, and fall-prevention programs offers the most realistic path forward in combating sarcopenia and frailty in aging populations.

CONCLUSION

Musculoskeletal and bone disorders remain a major contributor to global morbidity, particularly within aging populations where degenerative and inflammatory processes converge. Advances in pharmacology have reshaped therapeutic paradigms, moving beyond symptomatic relief toward targeted interventions that influence the biology of bone and muscle. Anti-resorptive therapies such as bisphosphonates and denosumab continue to provide the backbone of osteoporosis management, while anabolic agents including PTH analogs and romosozumab offer new opportunities to rebuild skeletal architecture in high-risk patients. Despite these gains, long-term safety concerns and cost considerations highlight the need for careful patient selection and sequential treatment strategies.

In osteoarthritis, the absence of an approved disease-modifying drug underscores the limitations of current approaches, which remain largely symptomatic. Ongoing efforts to develop DMOADs, regenerative injections, and biologics may ultimately provide structural benefits, but translation into routine clinical practice requires overcoming challenges related to efficacy endpoints and safety. Similarly, sarcopenia and frailty continue to represent unmet therapeutic needs, where myostatin inhibitors, SARMs, and metabolic modulators show promise but have yet to demonstrate consistent functional improvements. Lifestyle interventions, particularly exercise and nutritional optimization, remain indispensable in this context.

The role of biologics in inflammatory arthritides, alongside localized intra-articular therapies and integrative measures such as vitamin D supplementation and fall-prevention programs, illustrates the multidisciplinary nature of musculoskeletal care. Taken together, therapeutic advances are gradually transforming outcomes for patients with musculoskeletal disorders, but the future lies in a more integrated model that combines pharmacological, biological, and lifestyle interventions. Continued translational research, patient-centered clinical trials, and long-term monitoring are essential to achieve durable improvements in bone and muscle health. By aligning innovative science

with holistic care, the burden of musculoskeletal and bone disorders can be meaningfully reduced in the decades ahead.

REFERENCES

1. Reginster JY, Beaudart C, Buckinx F, Bruyère O. Osteoporosis and sarcopenia: Two diseases or one? Curr Opin Clin Nutr Metab Care. 2016;19(1):31–6.
2. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: A new immune–metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576–90.
3. Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 2017;5(11):908–23.
4. Canalis E. Wnt signalling in osteoporosis: Mechanisms and novel therapeutic approaches. Nat Rev Endocrinol. 2018;14(10):575–90.
5. Xia S, Zhang X, Zheng S, Khanabdali R, Kalionis B, Wu J, Wan W, Tai X. An update on inflamm-aging: Mechanisms, prevention, and treatment. J Immunol Res. 2016;2016:8426874.
6. Bone HG, Chapurlat R, Brandi ML, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: Results from the FREEDOM extension. J Clin Endocrinol Metab. 2013;98(11):4483–92.
7. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412–20.
8. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.
9. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532–43.
10. Drake MT, Clarke BL, Khosla S. Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032–45.
11. Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of denosumab therapy for osteoporosis: A systematic review and position statement. Bone. 2017;105:11–7.
12. Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254–62.
13. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41.
14. Miller PD. Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep. 2008;6(1):12–6.
15. Cosman F, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375:1532–43.
16. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–27.
17. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med. 2005;353(6):555–65.
18. Saag KG, et al. Romosozumab or alendronate for fracture prevention. N Engl J Med. 2017;377:1417–27.
19. Reid IR. Safety of romosozumab in osteoporosis. Lancet Diabetes Endocrinol. 2019;7(6):408–9.
20. Martel-Pelletier J, Barr AJ, Cicuttini FM, et al. Osteoarthritis. Nat Rev Dis Primers. 2016;2:16072.

21. Hochberg MC, Guermazi A, Guehring H, et al. Effect of intra-articular sprifermin on cartilage thickness in knee osteoarthritis: The FORWARD randomized trial. JAMA. 2019;322(14):1360–70.
22. Hochberg MC. Serious joint-related adverse events in randomized controlled trials of anti–nerve growth factor monoclonal antibodies. Osteoarthritis Cartilage. 2016;24(6):1049–56.
23. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745–59.
24. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578–89.
25. Grosser T, Smyth E, FitzGerald GA. Anti-inflammatory, antipyretic, and analgesic agents; pharmacotherapy of gout. In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill; 2018. p. 671–716.
26. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519–29.
27. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001;120(3):594–606.
28. Grosser T, et al. Pharmacology of COX inhibitors. Annu Rev Pharmacol Toxicol. 2017;57:171–91.
29. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31.
30. Rooks D, Praestgaard J, Hariry S, et al. Treatment of sarcopenia with bimagrumab: Results from a phase II trial. J Am Geriatr Soc. 2017;65(9